Cleocin is essentially a regional brand with a narrow international footprint. It is registered in just five countries — Italy, the United States, Turkey, Taiwan, and South Korea — a scattered rather than clustered distribution that spans North America, southern Europe, and parts of East Asia. A traveller arriving outside these markets is unlikely to find the Cleocin brand on a pharmacy shelf, even though its active ingredient is broadly available worldwide.
The active ingredient in Cleocin is clindamycin phosphate, classified as an antibacterial agent with bacteriostatic activity, and also used in topical antiacne and gynaecological anti-infective formulations. It is prescribed across a range of bacterial infections — including soft tissue infections, abscesses, lung abscess, peritonitis, bacterial vaginosis, and colitis — as well as for acne when used topically. The structured indication list further down this page details each registered use as recognised by national regulators.
Outside the handful of countries where Cleocin is registered, clindamycin is generally available under different brand names and across a variety of formulations — oral, topical, vaginal, and injectable — depending on the indication. Patients who have been prescribed Cleocin in one country and are travelling or relocating to another will usually find clindamycin-containing therapy available in the destination market, but under an unfamiliar label. A local pharmacist familiar with the regional formulary is the right person to identify the equivalent product and confirm whether the formulation matches the prescribed use.
Other antibacterial agents from related classes are also distributed internationally, although they are not freely interchangeable with clindamycin. Antibiotic selection is closely tied to the specific infection and the patient's clinical context, and any substitution or change in therapy should be made by the prescribing healthcare provider rather than improvised across borders.
Cleocin is prescribed across a range of bacterial infections, including soft tissue infections, abscesses, lung abscess, peritonitis, bacterial vaginosis, and colitis, as well as topical use for acne. The breadth reflects the activity of clindamycin against several types of bacteria. The structured indication block further down this page lists each registered use as recognised by the regulators in the markets where Cleocin is sold.
Cleocin contains clindamycin phosphate, an antibacterial agent with bacteriostatic activity, also formulated for topical antiacne use and for gynaecological anti-infective preparations. Clindamycin is used internationally under a number of different brand names and formulations, depending on the country and the route of administration, so the same molecule may appear on shelves abroad without the Cleocin label.
Cleocin is registered in five countries: Italy, South Korea, Taiwan, Turkey, and the United States. Beyond this small set of markets the specific Cleocin brand is rarely encountered, although clindamycin itself is widely available worldwide under other brand names and in various formulations. If your country is not on this list, a local pharmacist can confirm what clindamycin-containing product is available.
Clindamycin is sold internationally under several brand names, both as systemic preparations and as topical or gynaecological products, and other antibacterial agents in related classes are also widely available. Molecules within the broader antibacterial category are not interchangeable without medical guidance, since each has its own spectrum and prescribing context. To identify a clindamycin-containing product locally, search the active ingredient on Pill2Trip or ask a pharmacist.
Yes. Antibacterial therapy is calibrated to the type of infection, the suspected or confirmed organism, and the patient's individual circumstances, and prescription rules for antibiotics differ significantly between countries. Travellers and people relocating internationally should not improvise antibiotic substitution at a pharmacy counter. Any decision to start, continue, switch, or stop Cleocin should be made in consultation with a healthcare provider familiar with the patient.
